1 week Ago By ABMN Staff
Enovis Co. ( NYSE:ENOV – Get Free Report ) has received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company.
The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $69.13. Several research analysts recently issued reports on ENOV shares.
Evercore ISI dropped their price objective on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd.
JPMorgan Chase & Co. cut their price target on Enovis from $53.00 to $50.
00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Finally, Needham & Company LLC lowered their price objective on shares of Enovis from $82.00 to $65.
00 and set a “buy” rating for the company in a research note on Thursday, August 8th. View Our Latest Stock Analysis on ENOV Enovis Stock Up 0.8 % Enovis ( NYSE:ENOV – Get Free Report ) last released its quarterly earnings data on Wednesday, August 7th.
The company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.
03. The company had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.
99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.
06%. The firm’s quarterly revenue was up 22.6% on a year-over-year basis.
During the same period in the previous year, the company earned $0.61 EPS. Analysts anticipate that Enovis will post 2.
7 EPS for the current year. Institutional Trading of Enovis Hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Enovis by 3.
8% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,193,699 shares of the company’s stock worth $178,912,000 after purchasing an additional 117,209 shares in the last quarter. Diamond Hill Capital Management Inc.
boosted its holdings in Enovis by 14.5% in the second quarter. Diamond Hill Capital Management Inc.
now owns 2,786,034 shares of the company’s stock worth $125,929,000 after acquiring an additional 352,116 shares in the last quarter. DAVENPORT & Co LLC grew its stake in shares of Enovis by 5.5% during the first quarter.
DAVENPORT & Co LLC now owns 1,982,452 shares of the company’s stock worth $123,804,000 after acquiring an additional 103,027 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Enovis by 78.
6% during the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after acquiring an additional 665,208 shares during the last quarter.
Finally, Magnetar Financial LLC raised its position in shares of Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after purchasing an additional 442,051 shares during the last quarter.
98.45% of the stock is owned by hedge funds and other institutional investors. Enovis Company Profile ( Get Free Report Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Read More Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.
com's FREE daily email newsletter ..
